2024-11-13 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**1. Performance Comparison and Analysis:**

Eli Lilly and Co (LLY) is a leading pharmaceutical company that develops, manufactures, and markets pharmaceutical products. Its stock has outperformed the S&P 500 (VOO) significantly.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) | Cumulative Return (LLY) | Cumulative Return (VOO) |  Difference | Relative I.D. |
|------------|------|------|-------|------|-------|--------------------------|---------------------------|--------------|----------------|
| 2015-2017  | 30.4% | 18.8% | -8.0% | 0.8 | 80.2 |  926.4                    | 179.55                   |  746.85     | 79.0           |
| 2016-2018  | 50.8% | 18.8% | 18.5% | 0.7 | 109.8 |                         |                           |              |                |
| 2017-2019  | 89.5% | 16.8% | 37.8% | 0.7 | 124.8 |                         |                           |              |                |
| 2018-2020  | 113.2% | 21.9% | 65.8% | 0.7 | 160.3 |                         |                           |              |                |
| 2019-2021  | 154.6% | 21.9% | 54.6% | 0.7 | 262.2 |                         |                           |              |                |
| 2020-2022  | 190.4% | 21.9% | 166.8%| 0.7 | 347.3 |                         |                           |              |                |
| 2021-2023  | 266.0% | 18.6% | 231.1%| 0.5 | 553.4 |                         |                           |              |                |
| 2022-2024  | 210.4% | 19.0% | 179.9%| 0.6 | 790.2 |                         |                           |              |                |

* **Alpha** is a measure of the stock's performance compared to the benchmark (S&P 500) taking into account risk. A positive Alpha indicates that LLY has outperformed the benchmark, while a negative Alpha means it has underperformed. 
* **Beta** measures the volatility of a stock compared to the benchmark. A Beta of 1 indicates that the stock's volatility is the same as the benchmark, while a Beta greater than 1 indicates higher volatility.
* **Market Capitalization (Cap)** is the total value of all outstanding shares.
* **Current I.D. (Relative I.D.)** shows the current relative strength of the stock compared to the benchmark.  

**2. Recent Price Movement:**

* **Closing Price:** 820.03
* **5-day Moving Average:** 811.57
* **20-day Moving Average:** 860.94
* **60-day Moving Average:** 901.11

The stock is currently trading below all moving averages, indicating a short-term downtrend.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 31.07 - This suggests the stock is oversold.
* **PPO (Percentage Price Oscillator):** -0.39 - A negative value indicates a downtrend.
* **Delta_Previous_Relative_Divergence:** -13.23 (-) - This shows a negative divergence, indicating a weakening trend.
* **Expected Return:** 116.18% - This suggests a significant potential upside return compared to the S&P 500 for long-term investors (2+ years).

**4. Recent Earnings and Outlook:**

| Date        | EPS | Revenue |
|-------------|-----|---------|
| 2024-10-30  | 1.08 | 11.44 B$ |
| 2024-08-08  | 3.29 | 11.30 B$ |
| 2024-04-30  | 2.49 | 8.77 B$ |
| 2023-11-02  | -0.06 | 9.50 B$ |
| 2024-10-30  | -0.06 | 9.50 B$ |

The latest earnings announcement on 2024-10-30 was a positive surprise, exceeding analyst expectations. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2024-09-30  | $11.44B | 81.02%         |
| 2024-06-30  | $11.30B | 80.80%         |
| 2024-03-31  | $8.77B  | 80.91%         |
| 2023-12-31  | $9.35B  | 80.88%         |
| 2023-09-30  | $9.50B  | 80.42%         |

Eli Lilly has consistently maintained high profit margins, indicating strong profitability and efficient operations.

**2) Capital and Profitability:**

| Quarter      | Equity   | ROE |
|--------------|----------|-----|
| 2024-09-30  | $14.24B | 6.81% |
| 2024-06-30  | $13.56B | 21.88% |
| 2024-03-31  | $12.81B | 17.51% |
| 2023-12-31  | $10.77B | 20.33% |
| 2023-09-30  | $11.22B | -0.51% |

ROE (Return on Equity) shows how effectively a company uses its shareholder's investment to generate profit. It demonstrates the company's ability to generate profits from its assets.

**6. News and Recent Issues:**

Recent news and analyst opinions will be added here upon request.

**7. Comprehensive Analysis:**

Eli Lilly is a well-established pharmaceutical company with a strong financial performance and a history of outperforming the market. The stock is currently oversold, but its strong fundamentals and long-term growth prospects suggest a potential for upside return.

**8. Recommendations:**

While the stock is currently in a short-term downtrend, its long-term prospects remain strong, making it a potentially attractive investment for long-term investors who are willing to hold through short-term fluctuations. 
